Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012, Article ID 978531, 6 pages
http://dx.doi.org/10.1155/2012/978531
Review Article

Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

Division of Medical Oncology, University of Colorado Denver School of Medicine, 12801 E. 17th Avenue, Room L18-8117, Aurora, CO 80045, USA

Received 4 August 2011; Accepted 20 December 2011

Academic Editor: Hirotsugu Uemura

Copyright © 2012 Xiaoyu Hou and Thomas W. Flaig. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at PubMed
  2. R. Siegel, E. Ward, O. Brawley, and A. Jemal, “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths,” CA Cancer Journal for Clinicians, vol. 61, no. 4, pp. 212–236, 2011. View at Publisher · View at Google Scholar · View at PubMed
  3. F. A. Schutz and W. K. Oh, “Neoadjuvant and adjuvant therapies in prostate cancer,” Urologic Clinics of North America, vol. 37, no. 1, pp. 97–104, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. Machtens, D. Schultheiss, M. Kuczyk, M. Truss, and U. Jonas, “The history of endocrine therapy of benign and malignant diseases of the prostate,” World Journal of Urology, vol. 18, no. 3, pp. 222–226, 2000. View at Google Scholar · View at Scopus
  5. C. Huggins and C. V. Hodges, “Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941,” Journal of Urology, vol. 168, no. 1, pp. 9–12, 2002. View at Google Scholar · View at Scopus
  6. F. Labrie, “Adrenal androgens and intracrinology,” Seminars in Reproductive Medicine, vol. 22, no. 4, pp. 299–309, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. L. Mohler, M. A. Titus, and E. M. Wilson, “Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone,” Clinical Cancer Research, vol. 17, no. 18, pp. 5844–5849, 2011. View at Google Scholar
  8. C. Cai and S. Balk, “Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy,” Endocrine-Related Cancer, vol. 18, no. 5, pp. 175–182, 2011. View at Google Scholar
  9. C. Serrate, Y. Loriot, T. De La Motte Rouge et al., “Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer,” Annals of Oncology, vol. 20, no. 5, p. 965, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. T. Granfors, H. Modig, J. E. Damber, and R. Tomic, “Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone,” Journal of Urology, vol. 176, no. 2, pp. 544–547, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. P. Chrisp and K. L. Goa, “Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions,” Drugs, vol. 41, no. 2, pp. 254–288, 1991. View at Google Scholar · View at Scopus
  12. M. Marberger, A. V. Kaisary, N. D. Shore et al., “Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a phase III, open-label, international multicenter study,” Clinical Therapeutics, vol. 32, no. 4, pp. 744–757, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. R. S. Kirby, J. M. Fitzpatrick, and N. Clarke, “Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer,” BJU International, vol. 104, no. 11, pp. 1580–1584, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. Mahler, J. Verhelst, and L. Denis, “Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer,” Clinical Pharmacokinetics, vol. 34, no. 5, pp. 405–417, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. H. C. Shen and S. P. Balk, “Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer,” Cancer Cell, vol. 15, no. 6, pp. 461–463, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. B. K. Choi, C. H. Park, and C. I. Kim, “Comparison of ketoconazole-prednisolone combination therapy with prednisolone alone in patients with hormone refractory prostate cancer,” Korean Journal of Urology, vol. 41, pp. 1183–1189, 2000. View at Google Scholar
  17. I. Tannock, M. Gospodarowicz, W. Meakin, T. Panzarella, L. Stewart, and W. Rider, “Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response,” Journal of Clinical Oncology, vol. 7, no. 5, pp. 590–597, 1989. View at Google Scholar · View at Scopus
  18. T. W. Flaig and L. M. Glodé, “Management of the side effects of androgen deprivation therapy in men with prostate cancer,” Expert Opinion on Pharmacotherapy, vol. 9, no. 16, pp. 2829–2841, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. L. Klotz, I. McNeill, and N. Fleshner, “A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma,” Journal of Urology, vol. 161, no. 1, pp. 169–172, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Nanda, M. H. Chen, M. H. Braccioforte, B. J. Moran, and A. V. D'Amico, “Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction,” Journal of the American Medical Association, vol. 302, no. 8, pp. 866–873, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. W. D. Figg, S. Woo, W. Zhu et al., “A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer,” Journal of Urology, vol. 183, no. 6, pp. 2219–2226, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. E. S. Antonarakis and M. A. Eisenberger, “Expanding treatment options for metastatic prostate cancer,” The New England Journal of Medicine, vol. 364, no. 21, pp. 2055–2058, 2011. View at Google Scholar
  23. E. Deutsch, L. Maggiorella, P. Eschwege, J. Bourhis, J. C. Soria, and B. Abdulkarim, “Environmental, genetic, and molecular features of prostate cancer,” Lancet Oncology, vol. 5, no. 5, pp. 303–313, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. S. Dutt and A. C. Gao, “Molecular mechanisms of castration-resistant prostate cancer progression,” Future Oncology, vol. 5, no. 9, pp. 1403–1413, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. W. P. Harris, E. A. Mostaghel, P. S. Nelson, and B. Montgomery, “Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion,” Nature Clinical Practice Urology, vol. 6, no. 2, pp. 76–85, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. D. A. Loblaw, K. S. Virgo, R. Nam et al., “Initial hormonal management of Androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 Update of an American society of clinical oncology practice guideline,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1596–1605, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. I. F. Tannock, R. de Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. D. P. Petrylak, C. M. Tangen, M. H. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. T. S. Vasaitis, R. D. Bruno, and V. C. Njar, “CYP17 inhibitors for prostate cancer therapy,” Journal of Steroid Biochemistry and Molecular Biology, vol. 125, no. 1-2, pp. 23–31, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. H. Reid, G. Attard, E. Barrie, and J. S. de Bono, “CYP17 inhibition as a hormonal strategy for prostate cancer,” Nature Clinical Practice Urology, vol. 5, no. 11, pp. 610–620, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. G. Attard, A. H. M. Reid, R. A'Hern et al., “Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 27, no. 23, pp. 3742–3748, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. A. H. Reid, G. Attard, D. Danila et al., “Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate,” Journal of Clinical Oncology, vol. 28, no. 9, pp. 1489–1495, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. R. Dreicer, D. B. Agus, G. R. MacVicar, J. Wang, D. MacLean, and W. M. Stadler, “Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study,” Journal of Clinical Oncology, vol. 28, no. 15, supplement 3084, p. 15s, 2010. View at Google Scholar
  34. D. P. Petrylak, “Current clinical trials in castrate-resistant prostate cancer,” Current Urology Reports, vol. 12, no. 3, pp. 3–179, 2008. View at Google Scholar
  35. T. S. Vasaitis, R. D. Bruno, and V. C. Njar, “CYP17 inhibitors for prostate cancer therapy,” Journal of Steroid Biochemistry and Molecular Biology, vol. 125, no. 1-2, pp. 23–31, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. A. Molina and A. Belldegrun, “Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling,” The Journal of Urology, vol. 185, no. 3, pp. 787–794, 2011. View at Google Scholar
  37. J. S. de Bono, C. J. Logothetis, A. Molina et al., “Abiraterone and increased survival in metastatic prostate cancer,” The New England Journal of Medicine, vol. 364, no. 21, pp. 1995–2005, 2011. View at Google Scholar
  38. Y. Chen, C. L. Sawyers, and H. I. Scher, “Targeting the androgen receptor pathway in prostate cancer,” Current Opinion in Pharmacology, vol. 8, no. 4, pp. 440–448, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. C. Tran, S. Ouk, N. J. Clegg et al., “Development of a second-generation antiandrogen for treatment of advanced prostate cancer,” Science, vol. 324, no. 5928, pp. 787–790, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. H. I. Scher, T. M. Beer, C. S. Higano et al., “Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study,” The Lancet, vol. 375, no. 9724, pp. 1437–1446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. W. R. Foster, B. D. Car, H. Shi et al., “Drug safety is a barrier to the discovery and development of new androgen receptor antagonists,” Prostate, vol. 71, no. 5, pp. 480–488, 2011. View at Publisher · View at Google Scholar · View at PubMed
  42. C. Massard and K. Fizazi, “Targeting continued androgen receptor signaling in prostate cancer,” Clinical Cancer Research, vol. 17, no. 12, pp. 3876–3883, 2011. View at Google Scholar
  43. H. van Poppel, “Evaluation of degarelix in the management of prostate cancer,” Cancer Management and Research, vol. 2, no. 1, pp. 39–52, 2010. View at Google Scholar · View at Scopus
  44. P. J. Pommerville and J. G. de Boer, “GnRH antagonists in the treatment of advanced prostate cancer,” The Canadian Journal of Urology, vol. 17, no. 2, pp. 5063–5070, 2010. View at Google Scholar · View at Scopus
  45. L. Klotz, L. Boccon-Gibod, N. D. Shore et al., “The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer,” BJU International, vol. 102, no. 11, pp. 1531–1538, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. F. H. Schröder, B. Tombal, K. Miller et al., “Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study,” BJU International, vol. 106, no. 2, pp. 182–187, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. R. S. Raddin, C. M. Walko, Y. E. Whang et al., “Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer,” Anti-Cancer Drugs, vol. 22, no. 3, pp. 299–302, 2011. View at Google Scholar
  48. C. J. Ryan and D. J. Tindall, “Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically,” Journal of Clinical Oncology, vol. 29, no. 27, pp. 3651–3658, 2011. View at Google Scholar